Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021)
Inhibikase Therapeutics' (IKT) quarterly Notes Payables came in at $248911.0 in Q4 2021, up 485.2% year-on-year from $42534.0 in Q4 2020, and little changed on a QoQ basis from $248911.0 in Q3 2021.
Inhibikase Therapeutics (IKT) Notes Payables (2020 - 2021) Analysis & Trends
Inhibikase Therapeutics (IKT) has 2 years of Notes Payables data on file, last reported at $248911.0 in Q4 2021.
- On a quarterly basis, Notes Payables rose 485.2% year-over-year to $248911.0 in Q4 2021; TTM through Dec 2021 was $248911.0, a 485.2% increase from a year earlier, with the FY2021 full-year figure at $248911.0, up 485.2% from the prior year.
- Notes Payables for Q4 2021 stood at $248911.0, roughly flat from $248911.0 in the prior quarter.
- Over the last five years, Notes Payables for IKT reached as high as $994789.0 in Q1 2021 and fell as low as $42534.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 248,911.00 |
| Sep 30, 2021 | 248,911.00 |
| Mar 31, 2021 | 994,789.00 |
| Dec 31, 2020 | 42,534.00 |